Thanks Asked about CLRB---Have to know management.

They could not keep price about a buck on 8.6 million shares and over 30% owned by friendly institutions. Management owns little so another reverse split is likely just before funding like last two fundings.

CLRB Financial Mode of Operations—-


Question Are we likely to have more future stock splits and then large private placements with small group of institutions????? Cash Burn rate is approx. $ 2.5 million quarter.

CLRB has a history of doing large stock splits and then right after doing large private placements with warrants with small group of institutions (assume friends of CLRB—)

Notice prices over last five years— 20 for 1 Reverse Split 6/13/14 57,394,780 shares to 2,869,739 shares and another 10 for 1 Reverse Split 3/7/16 8,581,400 shares to 858,140 shares (WOW !! WHY????? OUCH !!)

If you purchased a share of CRLB on June 12, 2014 for $ .35 a share today your cost would be $ 70 share because of the 20:1 and 10:1 stock splits.

If you purchased a share of CRLB on March 4, 2016 for $ .44 a share your cost per share today would be $ 4.40 share. because of the 10:1 stock split on 3/7/16.

The 3/7/16 reverse stock split is shocking. The CEO came on board CLRB on 6/15/15 so this was on his watch.

SEE THIS to see impact of reverse stock splits on CRLB—

http://investor.cellectar.com/stocklookup.cfm

Interesting Financial Mode for the small group of institutions—-primarily from Wisconsin, the home of CLRB.

What do you all say??? Anyone understand Management here? Another stock split in late 2017??

$ARTH ARCH THERAPEUTICS "The WD-40 of Biotech"

How could a clear liquid be classified as a medical device??


There are over 200 potential applications for this clear liquid medical device! 200 !!


Arch is run by a CEO who is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund. Dr. Terrence Norchi is the CEO



Elevator Summary of ARCH www.archtherapeutics.blogspot.com

Arch (ARTH) CEO Dr. Norchi UP CLOSE AND PERSONAL

archtherapeutics.blogspot.com/2016/12/arch-arth-ceo-dr.html

Dr. Norchi Presentation 12/7/16

http://2016archtherapeuticsanalysis.blogspot.com/2016/12/dr-norchi-presentation-arth-arch.html


ARCH THERAPEUTICS (ARTH) CATALOG OF ARTICLES AND VIDEOS

archtherapeutics.blogspot.com/2016/12/therapeutics-arth-catalog-of-articles.html


ARCH THERAPEUTICS (ARTH) EXPANSION OF PRODUCT LINES AND INTELLECTUAL PROPERTY—THE REAL STORY OF 2016

archtherapeutics.blogspot.com/2016/12/expansion-of-product-lines-and.html



Here is 2016 Arch Financial Summary—Note that 95% of the 2019 Series A warrants have been exercised-amazing-Note all the cash generated from Warrant exercise--$5 million cash on hand to last to 4th quarter 2017 (9/30/17)

http://2016archtherapeuticsanalysis.blogspot.com/

"Arch is a biotech company building a patent ESTATE and the ESTATE we hope will generate a lot of product opportunities in a range of areas---as you can see on Slide 22 there is a wide range of opportunities."

Company Presentation See Page 22:
http://content.equisolve.net/archtherapeutics/media/c6dc3c52a4e0458fae43779086460ea0.pdf

Warrant Holders are no longer a problem---If you hold 2020 or 2021 warrants why would you exercise in 2016?

Here is 2016 Arch Financial Summary—Note that 95% of the 2019 Series A warrants have been exercised-amazing-Note all the cash generated from Warrant exercise–$5 million cash on hand to last to 4th quarter 2017 (9/30/17)

http://2016archtherapeuticsanalysis.blogspot.com/

Nada. zero. Zilch.It is a function of price-unDer $ 5.

$ARTH Form 10-K comments 9/30/16


$ARTH I have completed about half of my review of Arch’s recently filed Form 10-K. Here are my comments. I am of course hopelessly biased starting back in October 2014.

With human clinical data completed surprised that we have zero institutional ownership. Dr. Norchi will complete his tenth presentation in 2016 this afternoon to a empty room…….and as always stock should be down tomorrow….. He has the best presentation in the bio universe. (See comments on this conference-changes everything--Dr. Norchi is taking Arch to new level)

1) Comment: could be one or more collaboration agreements or strategic partnership….. More is better as it delays Arch being swallowed too early

“Commercialization

Our long-term commercialization plan for at least some of our product candidates could entail entering into one or more collaboration agreements or strategic partnerships. Based on our current general approach and strategy of utilizing the expertise and resources of third party service providers and maintaining a relatively small internal team, we currently expect that we may pursue some degree of strategic collaborations or partnerships with third parties, which could include licensing arrangements, distribution and supply partnerships, engagement of external regulatory experts and/or marketing and sales teams, among other types of potential relationships. We presently believe that certain relationships could improve our ability to obtain regulatory approval for our product candidates and attain market acceptance for and profitable sales of those product candidates, and that our current and planned activities and milestones relating to AC5 are well-aligned with the needs of the market and potential partners and collaborators that may wish to enter or expand their presence in our target markets.

We envision the potential future customers in the marketplace for AC5 and any other hemostatic or sealant agent we may pursue will include surgeons and other doctors, government agencies such as the Department of Defense, hospital and operating room management and ambulance and other trauma specialists.”

2) Comment: The last part of this sentence is important as they have intellectual property extending beyond AC5’s 200 +- applications:

“We expect that we will pursue approvals for use of AC5 as a hemostatic agent and wound care agent in surgical and dermatological settings, and we may also seek to obtain approvals for additional potential indications for use of the product, which we may pursue either opportunistically or once initial regulatory approval for the product is obtained.”

3) Comment: This use to be my favorite statement to see in Arch’s past SEC filings. Reason is it is the amount is extremely small. Arch has replaced the statement with a nebulous one talking about $ 5,000,000 @*%#$%?

“In particular, we currently estimate that in order to support our business operations as well as obtain regulatory approval of AC5 in the U.S. and Europe we will require up to $8,000,000 to $12,000,000 and potentially more in additional capital. Our future capital requirements will depend on many factors, including:”

2016

“In addition to capital required for operating expenses, depending upon additional input form EU and US regulatory authorities, as well as the potential for more than one regulatory filing and approval in 2017, up to $5,000,000 may be required to complete an initial European CE Mark approval and an initial US regulatory clearance or approval.”

4) Here is 2016 Arch Financial Summary—Note that 95% of the 2019 Series A warrants have been exercised-amazing-Note all the cash generated from Warrant exercise–$5 million cash on hand to last to 4th quarter 2017 (9/30/17)

http://2016archtherapeuticsanalysis.blogspot.com/

More warrant exercise after 9/30/16 year end

“During the period commencing October 1, 2016 and ending on December 2, 2016 additional Series A warrants have been exercised for an aggregate issuance of 1,100,000 shares of the Company’s Common Stock at and exercise price of $0.20 per share, resulting in gross proceeds of $220,000. In addition, Series E warrants have been exercised for an aggregate issuance of 125,000 shares of the Company’s Common Stock at an exercise price of $0.438 per share, resulting in gross proceeds of $54,750.”

5) Here is the real story for 2016 regarding Arch—Expansion of intellectual property.

“Our patent portfolio includes a total of 23 patents and applications assigned to Arch Biosurgery, Inc. This portfolio covers self-assembling peptides and methods of use thereof, and includes five patents that have been either allowed, issued or granted, and eighteen pending applications in nine jurisdictions.”

See write-up

ARCH THERAPEUTICS (ARTH) EXPANSION OF PRODUCT LINES AND INTELLECTUAL PROPERTY—THE REAL STORY OF 2016

http://archtherapeutics.blogspot.com/2016/12/expansion-of-product-lines-and.html

6) Comment: Perhaps you missed Dr. Norchi’s recent article:

Stopping the Bleeding—a Better Hemostatic Device

Fri, 12/02/2016 – 11:31am R&D Magazine

by Terrence W. Norchi, President & CEO, Arch Therapeutics

https://www.rdmag.com/article/2016/12/stopping-bleeding-better-hemostatic-device

7) Comment Other——If you never tire of doing your due diligence here is a cumulative Arch collection—if anything is missing please let me know:

ARCH THERAPEUTICS (ARTH) CATALOG OF ARTICLES AND VIDEOS

http://archtherapeutics.blogspot.com/2016/12/therapeutics-arth-catalog-of-articles.html

Elevator Summary of ARCH http://www.archtherapeutics.blogspot.com

Arch Therapeutics, Inc.
LD Micro Main Event 2016
December 6, 2016 - December 8, 2016

Listen here:

http://wsw.com/webcast/ldmicro11/arth/index.aspx

Warning: If you listen to this you are going to feel you do not own enough.


Arch has morphed into another company right before our eyes.

I wrote about it here:

ARCH THERAPEUTICS (ARTH) EXPANSION OF PRODUCT LINES AND INTELLECTUAL PROPERTY—THE REAL STORY OF 2016

http://archtherapeutics.blogspot.com/2016/12/expansion-of-product-lines-and.html

Arch's new Company theme:

"Arch is a biotech company building a patent ESTATE and the ESTATE we hope will generate a lot of product opportunities in a range of areas---as you can see on Slide 22 there is a wide range of opportunities."

See page 22 So there are 200 +- products related to AC5---Arch is patenting a fleet of other products---building intellectual property war chest which will be the real value when Arch is sold

The reason this is happening is that Arch has one of the best Peptide scientists in the world--Dr. Steve Kates--he perfected AC5 which was crude coming out of MIT to what it is today. Dr. Kates is VP Technology and has been with Arch since 2007.

Arch Presentation see page 22

http://content.equisolve.net/archtherapeutics/media/c6dc3c52a4e0458fae43779086460ea0.pdf

ARCH 2017

Submit in US 510 (K)
PMA-surgical trial for internal use to commence
CE Mark submitted in early 2017
"Label expansion strategy to commence in 2017 with data from internal US surgical trial
File additional patent applications to expand the patent Estate

Comment: Likely to have multiple partners--value of Arch is enhanced with patent ESTATE

Per Form 10-K

"Commercialization

Our long-term commercialization plan for at least some of our product candidates could entail entering into one or more collaboration agreements or strategic partnerships. Based on our current general approach and strategy of utilizing the expertise and resources of third party service providers and maintaining a relatively small internal team, we currently expect that we may pursue some degree of strategic collaborations or partnerships with third parties, which could include licensing arrangements, distribution and supply partnerships, engagement of external regulatory experts and/or marketing and sales teams, among other types of potential relationships. We presently believe that certain relationships could improve our ability to obtain regulatory approval for our product candidates and attain market acceptance for and profitable sales of those product candidates, and that our current and planned activities and milestones relating to AC5 are well-aligned with the needs of the market and potential partners and collaborators that may wish to enter or expand their presence in our target markets.

We envision the potential future customers in the marketplace for AC5 and any other hemostatic or sealant agent we may pursue will include surgeons and other doctors, government agencies such as the Department of Defense, hospital and operating room management and ambulance and other trauma specialists."

I just listened to the conference. We have a new company with new theme announced at very end by Dr. Norchi. We are going to have all kinds of product lines.... This is good because no one can buy Arch out for a song. The intellectual property is the key for Arch. Norchi is building an "estate of intellectual propery."


The more publicity the better. Just have people go read this:

Elevator Summary of ARCH http://www.archtherapeutics.blogspot.com

ARCH THERAPEUTICS (ARTH) CATALOG OF ARTICLES AND VIDEOS

http://archtherapeutics.blogspot.com/2016/12/therapeutics-arth-catalog-of-articles.html


ARCH THERAPEUTICS (ARTH) EXPANSION OF PRODUCT LINES AND INTELLECTUAL PROPERTY—THE REAL STORY OF 2016

http://archtherapeutics.blogspot.com/2016/12/expansion-of-product-lines-and.html

Arch (ARTH) CEO Dr. Norchi UP CLOSE AND PERSONAL


http://archtherapeutics.blogspot.com/2016/12/arch-arth-ceo-dr.html

Thanks Not a bad idea.....lol Stock would be.......

Please send the article to the company and request them to implement it....

http://cnafinance.com/arch-therapeutics-arth-stock-should-quit-walking-softly/12565


Arch Therapeutics ($ARTH) Stock: Should Quit Walking Softly!

Arch Therapeutics Inc (OTCMKTS: ARTH)

If I didn't know better, I would think that Arch Therapeutics was producing a magnet that sticks to numbers, instead of a highly successful medical device that can stop human bleeding very quickly.

At least if ARTH were producing magnets, I would understand why the ARTH share price has been sticking to the number 60 like a Disney World magnet on a Main Street refrigerator. Oh, that number 60 refers to 60¢, the level that ARTH has been clinging to for the past month. And, NOT for good reason.

ARTH Needs To Broadcast

Without a doubt, ARTH is well on the road to bringing a working medical device to market, one that can potentially transform the way wounds are treated in both trauma and surgical situations.

ARTH has developed the AC5, a medical device that utilizes self assembling peptides to produce a response in naturally occurring amino acids. The AC5 is designed to stop bleeding quickly, and human trials have shown a vast decrease in the time required to achieve hemostasis, the stopping of bleeding.

This is what gets me, though. [[color=red]b]Here you have a company like ARTH, one that is on the cusp of getting FDA approval as well as receiving the important Ce mark from Europe, and very few investors know about the story. ARTH is trading at less value than some bogus penny stock concoctions that regularly promise investors a product by next quarter, only to let them down with excuses for delay or postponement.[/color]

It's the perpetual game of shareholder rotation, one retail investor goes in and one goes out. A transfer of wealth, if you please. Only that in most cases it becomes the transfer of a big bag of worthless shares.

It can be different for ARTH though, and until management realizes that it has to actually market its company AND its products rather than to simply invent one, the stock will languish.

What Should ARTH Do?

First, ARTH needs to hire a professional Investor Relations company, one that can be a one-stop shop for drafting press releases, scheduling road shows, and more importantly, introducing the company to institutional-based investors that would quickly embrace the ARTH story and understand their potential.

[b]I'm not talking about engaging with a pump and dump firm, I am talking about letting ARTH grow up and begin to play with the bigger kids in the money pit.[/b] It's perfectly acceptable to hire a professional team to do what they do best - promote companies and make prime introductions to interested institutional parties. It allows ARTH to do what they do best, concentrate on refining the AC5 to ensure that it is the best and most viable coagulation option available to treating physicians.

The AC5 is demonstrating exceptional efficacy with regards to treating open wounds. The device has been used to stop the bleeding in intentionally made wounds as well as shown tremendous success when used during surgical procedures.

The time to hemostasis has demonstrated a 40% decrease over traditional cessation methods, clearly demonstrating the superiority of the AC5 against traditional treatment.

ARTH needs to tell the story. While coverage on financial sites may help expose the company to new investors, the type of investment partners that ARTH can attract is much grander. ARTH has results in hand and a multi-billion dollar addressable market that can employ the AC5, which offers a far better method of stopping bleeding than is currently available. But, if investors don't know about the product, the market value of the stock will continue to suffer.

Future Of ARTH

I am a believer that ARTH will eventually get its post pubescent growth spurt, however, the more time that ARTH management allows to slip by, the less value the shareholders may receive in a post-approval partnership.

Yes, trading on these podunk OTCBB markets don't help the cause, but ARTH can address that as well, as long as they put the right people in place to do the talking for them.

ARTH shouldn't be trading at 60¢, they should be well north of a dollar at this point in the evolutionary life cycle. Not only have they demonstrated superior results, they cleared the largest hurdle last month when they announced that the AC5 is just as effective in stopping bleeding for patients that are taking anti-coagulant medications. This was the one potential item that rightfully gave investors pause. But, now that that is cleared, the obstacles are about cash and exposure.

As far as the cash goes, ARTH is fine where they are. They don't need too much additional funding, as the company has never stated that they intended to market the AC5 on their own. A partnership should be in the cards, and ARTH can wait out the New Year until they sign one. Johnson and Johnson would fit the bill quite well, by the way.

The next obstacle, also easily cleared, is for management to take a very small chunk of cash and apply it toward building a professional reputation based on a credible product and enormous market potential. No pump and dump, simply the truth about what the AC5 has demonstrated in human trials and the addressable market potential for the device.

ARTH...State Your Name

ARTH, its time to state your name out loud, because at this point, very few investors know it. You have a great device with broad applications. The AC5 is highly praised by both surgeons and medical professionals as a revolutionary method to stop bleeding in patients.

ARTH, you have the medical endorsements and you have the management team in place. All you need now is a microphone. Although this article will reach many in the know, its time that you moved away from the retail play pit and hire a team that can develop the company on a socially acceptable, professional level. It's called company-based marketing.

Trust me, there are people who wish that they knew your name, or they will in a few months once you successfully bring the device to market. It's okay to give them a chance now, though.

Walking softly while carrying a big stick may have worked for Buford Pusser in "Walking Tall", but, in the real world of stock investing, ARTH needs to yell loudly and carry around a full briefcase of updated clinical results, the reports that you will hand out to potential investors during the road shows that you should be attending.

Once people know you, they will love you. C'mon, ARTH, don't be shy. You have one of the most revolutionary products on the verge of coming to market. It's time to tell the world.

Stopping the Bleeding—a Better Hemostatic Device


Fri, 12/02/2016 – 11:31am


by Terrence W. Norchi, President & CEO, Arch Therapeutics


R&D Magazine


https://www.rdmag.com/article/2016/12/stopping-bleeding-better-hemostatic-device


ARCH THERAPEUTICS (ARTH) CATALOG OF ARTICLES AND VIDEOS


http://archtherapeutics.blogspot.com/2016/12/therapeutics-arth-catalog-of-articles.html


Elevator Summary of ARCH http://www.archtherapeutics.blogspot.com

Spana's background is interesting. The two co-founders one of which is Spana own 6.1% which is mostly options ---2010 reverse split reduced co-founders interests because of subsequent capital finanings.

What is Spana's motivation is all this? Sell out? JV so salary of $400,000 continues?

Anyone here talk with Dr. Spana ever?

Carl Spana, Ph.D.

President, Chief Executive Officer and Director

Dr. Spana is a co-founder of Palatin, and has been our Chief Executive Officer and President since June 2000, and from June 1996 through 2000 was our executive vice president and chief technical officer. Previously Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. From 1991 to 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb where he was involved in scientific research in the field of immunology.
Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.

"21st Century Cures Act,” Changes Everything...

Among other things directs the FDA to speed up the approval process for new drugs and medical devices.

ACT Draft

The draft act itself is nearly 1,000 pages long and is found here:http://docs.house.gov/billsthisweek/20161128/CPRT-114-HPRT-RU00-SAHR34.pdf.

Section 3051 is interesting: “The purpose . . . [is] to apply efficient and flexible approaches to expedite the development of, and prioritize the Food and Drug Administration’s review of, devices that represent breakthrough technologies.” ($ARTH)



http://www.npr.org/sections/health-shots/2016/11/29/503759592/congress-poised-to-pass-sweeping-law-covering-fda-and-nih

Contact Arch IR Kirin ksmith@pcgadvisory.com

No new dilution. Focus on press releases. The S-3 is for both old issuances --warrants and new issuances. New issuances will be announced via press release. They have enough cash for now.

$PTN--I posted this on another board--If anyone has insights into the two co-founders intentions please post. Thank you.

1) Why do insiders only own 6.1% of the company? PTN was started in 1996 by Dr. Carl Spana –President (has merchant banking and medical venture capital experience) and Dr. John Prendergast-Chairman (has medical venture capital experience). Based upon this one would think they would own a large position. Dr. Spana is 53 years old.

Answer: PTN did a reverse split on September 27, 2010. This was a 1 for 10 reverse split, meaning for each 10 shares of PTN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. The two PTN cofounders had their positions reduced by reverse split. Note: since 2010 reverse split they have raised substantial $$$ which diluted the co-founders original positions.

So as of 6/9/16 proxy date co-founder Dr. Spana owned 1,559,339 share equivalents 2.3%—which is mostly options and some restricted stock awards. This excludes unvested options (297,500). His option prices range from $37.50 (reverse split !!) to $ .62. His average option per share looks to be north of $ 1. Wow !!


Based upon this I believe that they may use JV on bremleanotide to fund their other 3 PTN programs where they have spent $123.7 million to date. See below. Dr. Spana is young and may want to continue the R&D efforts. He would then be paid a large salary $462,500 for many years.

So as of 6/9/16 proxy date co-founder Dr. Prendergast owned 1,421,352 share equivalents 2.1%—which is mostly options and some restricted stock awards

Dr. Spana earns a cash salary of $462,500 and other compensation such as options, stock awards brining total to $ 1.138 million.

2) Will PTN merely do a JV on bremleanotide and us the cash flow to fund the other three PTN programs? This looks like this could happen as they have spent $123.7 million on the other programs ((which include PL-3994, PL-8177, other melanocortin receptor agonists, obesity, other discovery programs and terminated programs) They are not going to just walk away on these programs. Dr. Spana is young enough to desire to continue the R&D effort.

“Cumulative spending from inception to March 31, 2016 is approximately $224,500,000 on our bremelanotide program and approximately $123,700,000 on all our other programs (which include PL-3994, PL-8177, other melanocortin receptor agonists, obesity, other discovery programs and terminated programs).”

3/31/16 –Need $ 32 million

Management believes that the Phase 3 clinical trial program withbremelanotide, including regulatory filings for product approval, will cost at least $80,000,000, of which approximately $48,000,000 has been expensed to date.

I have posted this on another board. I am long PTN but a bit concerned about financials and management intentions. I am CPA so financials are my focus. I believe in science because of Dr. KSS of gumshoe. Dr. KSS is MD PHD and I have analyzed another Dr. KSS stock where the CEO is a MD, MIT MBA and former portfolio manager of Putnam $ 4 billion fund here:
ARTH http://www.archtherapeutics.blogspot.com/


$PTN Let me just make a quick overview comment on the financials and shares outstanding. This is a very complicated financial situation that is going to require more analysis. . Arch’s 6/30/15 financials were pristine compared to PTN. That is a reference point.

So it appears that there are 85,934,037 shares outstanding as of 9/16/16 when their Form 10-K was filed. As of 6/30/16 there were 112,508,356 warrants outstanding. Note that approximately 83 million of those are exercisable at one cent…… !! There is 5,261,740 option shares outstanding at 6/30/16.

The do complicated private placements whereby they issue shares at approximate market price and warrants at one cent. Not sure why on this?? They do have 20.771 million warrants at $1 share expiring 3/2/17 !!!

When you look at their balance sheet you really have to hold your nose. Wow…

BTW they show weighted average number of common shares fully diluted at 156,553,534 for 6/30/16…one of you mentioned this number

Since inception they have raised $ 325.1 million. They have a shareholders deficit of $17,585,667. Total assets of $ 11,051,735. Total liabilities of $28,637,702. I have to analyze these.

Your questions should be financial. They did do a private placement in August 2016 for approx. $9 million (complicated).
Bottom line in my opinion: They cannot do a JV fast enough…. They have to repair their balance sheet.

They are working on so many different fronts which someone needs to focus on. There is a lot here to evaluate.

I will post some analysis of the 6.1% ownership by insiders.

Heck I am not opposed to Lowcounty's DD at all. Have at it. I was only addressing that Avtar is irrelevant.

The author of the PTN article hangs out here: http://www.stockgumshoe.com/2016/09/tropic-of-palatin/

Make sure you read the authors articles on ARTH also.

Avtar is Chairman and lives in California and has zero to do with operations outside of Boston. Zero. Waste of time. He is a figurehead. Next..............

IMHO more likely that PTN will do a JV on bremleanotide and use the cash flow to fund the other three PTN programs.

This looks like this could happen as they have spent $123.7 million on the other programs ((which include PL-3994, PL-8177, other melanocortin receptor agonists, obesity, other discovery programs and terminated programs) They are not going to just walk away on these programs. Dr. Spana is young enough to desire to continue the R&D effort on the three.

“Cumulative spending from inception to March 31, 2016 is approximately $224,500,000 on our bremelanotide program and approximately $123,700,000 on all our other programs (which include PL-3994, PL-8177, other melanocortin receptor agonists, obesity, other discovery programs and terminated programs).”

To fully understate Dr. Norchi read this:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124100038

Ten years of his life since 2006. It was on his dime from 2006-2013 when went public. Gave up Putnam position. He and Chairman own approximately 24%.

CEO who is a MD, MIT MBA and Former Portfolio Manager at Putnam $4 Billion Healthcare Fund.

Elevator Summary of Arch http://www.archtherapeutics.blogspot.com/

Since Dr. Norchi has all his eggs in this basket one simply needs to follow his lead. However long that takes.

Why CEOs Should Understand Business On Top Of Their Specialization Author Dr. Terrence Norchi


July 10, 2016

Interesting insight in what Dr. Terrence Norchi thinks it takes to make a quality CEO.

http://www.ceo.com/operations/why-ceos-should-understand-business-on-top-of-their-specialization/

Arch Elevator Summary
http://www.archtherapeutics.blogspot.com/

Here is the ARCH executive that continues to expand its Peptide intellectual property:

Executive at ARCH who is world class peptide expert:


Steven A. Kates, PhD

VP of Technology

Steven Kates, PhD has worked with Arch Therapeutics since 2007. He is a highly experienced pharmaceutical executive with over twenty years in R&D for both life science products and human therapeutics, Dr. Kates is regarded as a world leading chemist and industry expert in peptide design and manufacture in the biopharmaceutical industry. He has advanced several compounds through drug development from early pre-clinical to early clinical development. He was responsible for the successful development of clinical candidates for both 505(b)2 and NCE applications. He has held senior positions at Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation.

Dr. Kates has authored or co-authored over 100 articles, reviews, and patents, and is a member of the American Chemical Society, the American Peptide Society, and the Association of BioMolecular Research Facilities. Dr. Kates has served as editor of Solid-Phase Synthesis: A Practical Guide and ADMET for Medicinal Chemists: A Practical Guide; guest editor of Biopolymers; co-editor of ADMET for Medicinal Chemists, A Practical Guide; a member of the Editorial Board of International Journal of Peptide Research and Therapeutics (formerly Letters in Peptide Science); and is an ad hoc reviewer for the NIH bio-organic and natural products study section.

An Adjunct Professor in the Bouvé College of Health and Sciences, Center for Drug Discovery and College of Professional Studies at Northeastern University, and Visiting Professor of Chemistry at Brandeis University, Dr. Kates earned his B.S. in chemistry from Bates College and his Ph.D. in Synthetic Organic Chemistry from Brandeis University, and conducted post-doctoral studies at The Massachusetts Institute of Technology. His research interests include solid-phase peptide and organic synthesis as well as synthesis of peptides and small molecules with therapeutic activities for stroke, coronary artery bypass graft (CABG), myocardial infarction (MI) and inhibitors and substrates for kinases, proteases and G-protein coupled receptors.

All anecdotal evidence is appreciated here. Yours happens to be a tad more important.

You always have great stories...BBQ's etc. I lived for many years in Ridgewood /NYC. great area.

I wonder when the doctors will come flooding into stock.

Did you attend Dr. Norchi's NYC presentation? Have you met him?

Since JNJ has 60% of the hemostasis market it is extremely important that they address Arch.

Arch ties to JNJ


1) Dr. Arthur L. J. Rosenthal, Ph.D., also known as Art serves as Advisor of Arch Therapeutics, Inc. He served as a Vice President of Research and Development at Johnson & Johnson Medical, Inc., from April 1990 to January 1994, and was in charge of worldwide research, development, regulatory, and clinical affairs for the JJMI Division—Google Arthur L. J. Rosenthal Ph.D. to see his impressive background.

2) retired former COO of Arch William Cotter was one of key officers of Closure Medical Corporation which was sold to JNJ in 2005.See Arch press release Arch Therapeutics Appoints Senior Management Team Members CAMBRIDGE, MA -- (Marketwired) -- 07/08/13

Johnson & Johnson and CLOSURE Medical Corporation Announce Acquisition Agreement

Acquisition to Strengthen Presence in Topical Adhesives and Surgical Sealants

NEW BRUNSWICK, N.J. and RALEIGH, N.C., March 4, 2005 $370 million

Dream about Arch doing a JV in Europe for external apps (say 125) on terms similar to following.


Study these recent deals to see how big the numbers have gotten:

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study (market cap $ 67 million---royalty in high teens)

"This morning, MEI $MEIP is taking the wraps off a development deal with Switzerland’s Helsinn designed to shepherd the HDAC inhibitor pracinostat through a pivotal study. MEI gets $20 million in near-term cash —$15 million up front with a $5 million milestone at the start of the Phase III — along with a $5 million equity investment. And there’s $444 million in milestones on the table for success, along with royalties that can be earned from Helsinn’s marketing efforts"


"Advaxis Inc. ADXS, +5.48% shares spiked 28% in pre-market trade Tuesday after the company announced a $40 million agreement with Amgen Inc. AMGN, -0.15% to develop and commercialize cancer immunotherapy treatment ADXS-NEO. The agreement includes a $40 million upfront payment to Advaxis and a $25 million purchase of the company's common stock by Amgen, along with sales milestone payments of up to $475 million and additional royalty payments based on global sales."

There will definitely be multiple trials going on at same time. The sooner the better.

My hope is that Arch may get some leeway for Euro trials with FDA. We will see.

The SEC filings says $ 8 to 12 million additional capital required FOR ALL AC5 applications in Europe and USA. THAT is TINY !!!!!!!

So guessing 3 in Europe and 3 in USA.

IMHO the vast majority of the 200 AC5 apps relate primarily to external so you can cover a lot of ground external human trial. IMHO most of the external apps are big ticket markets.

Why do you think Norchi is excited?

ARCH WHAT ULTIMATE VALUE?

This is all IMHO. I have no crystal ball.....

One has to start at the bottom with the sale of Closure Medical being sold in 2005 to JNJ for $370 million.

Several of the people from Closure have worked on Arch's AC5.

With 167.7 million shares fully diluted that means a market cap of $ 114 million or 31% of the $370 million. Stock is CHEAP IMHO.

With Arch's AC5 having 200 +- applications (many target markets representing Billions of $$) and fleet of new products from new patents Arch dwarfs Closure product imprint. Dwarfs.

What is the target market value for all AC5 200+- applications??

Dr. Norchi comment regarding the AC5 +- 200 applications plus new potential product pipeline. "My view is that they're all big, and there's lots of them and that's why we're pretty excited."


As someone pointed out it is like WD40 as far as applications.

New Patents and Products http://archtherapuetics.blogspot.com/2016/08/arch-therapeutics-arth-expansion-of.html


Dr. Norchi talked about valuation here:

Dr. Norchi stated in August 18, 2016 interview:

1) The list of how and where to further deploy the Arch technology continues to grow.
2) True value of Arch stems from it intellectual property.
3) Expansion of Intellectual property is value creation for Arch.
4) AC5 human trials is the first product and first application but a small step on a large valuation creation curve.
5) Desire to expand product labels
6) The Arch technology has the potential to be a real game changer for doctors and patients alike in reducing surgical times and reducing other risks….. resulting in better outcomes.


Arch Therapeutics’ President and CEO, Terrence Norchi, Featured on “Small Cap Spotlight” Podcast Discussing First Product, Clinical Trial Significance, CE Mark Process, and Other Items

August 18, 2016 --Note talk of product line expansion based upon intellectual property expansionNorchi interview in which he talks about expansion of product lines via Arch intellectual property

http://www.archtherapeutics.com/news/media/detail/1222/arch-therapeutics-president-and-ceo-terrence-n
orchi

The ultimate value of Arch is dependent on how long Dr. Norchi can remain independent. The value grows for the longer the period. What $ 1 billion market cap or $ 6 share or much higher?

The new products enhance the chance of remaining independent longer which is good news IMHO.

Elevator Summary of Arch http://www.archtherapeutics.blogspot.com/

People still deriving benefit from anatabine.....they think its nicotine--this is one of the areas they should have focused on--the biotech competition in psoriasis is substantial

Somebody who follows iHaveUC just wrote a new commentt to Does Smoking Really Help Ulcerative Colitis?.

Comment Link: http://www.ihaveuc.com/does-smoking-really-help-ulcerative-colitis/comment-page-3/#comment-2284263

Author: UCnomore
Comment:

I've had UC since 1996 (20 years) and was never a smoker. After doing some extensive research I decided in 2007 to try smoking to see if it would help my symptoms. At that time I was having about 6-8 movements per day (with blood), cramps etc. I smoked 1 cigarette and probably an hour later I had another movement.....NO BLOOD! Also, cramps subsided. I was sold and have been smoking no more that about 8 cigarettes per day since. I do know the negative sides of smoking but for me IT'S WORTH IT. As of 2012 I've been in remission!

Here's the link to the original story: http://www.ihaveuc.com/does-smoking-really-help-ulcerative-colitis/

Oh so you don't care about the FDA. Why because it is not 2018? I thought the FDA was pertinent to Titan.

"Thus far in 2016, 89 percent of FDA-submitted medical device applications have been pushed back by the FDA with a citation of at least one major deficiency.

This datum does place the plight of TransEnterix in interesting relief….almost as if it was gratuitously doomed.

That’s the highest in history.

The lowest was 40 percent in 2000."

They took one of the most difficult areas-- Psoriasis. They were never serious IMHO.

There was so many other easy routes to getting Anatabloc back on the market in Europe for example.

Williams?

We will not have to sell one more share in private placement.

posted previously*********

Future ARCH Financings

I am beginning to doubt whether there will be any future stock financings in light of what I am seeing in recent JV deals.

I see people are attempting to talk the Arch price down talking about stock financings. Look they had $ 5.7 million cash per recent 10-Q. I believe another $ 1.9 series E warrants were exercised recently. They burn $400,000 month. Thus 17 months of funding.

Study these and note size of numbers and dream about ARTH. Imagine if they did a deal for just 50 of the 200 potential applications.

Remember we only need $ 8 to $ 12 million of additional capital to get all the human trials in Europe AND USA per SEC filings. This is SMALL. A JV in Europe could take care of this easily.

Study these recent deals to see how big the numbers have gotten:

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study (market cap $ 67 million—royalty in high teens)

“This morning, MEI $MEIP is taking the wraps off a development deal with Switzerland’s Helsinn designed to shepherd the HDAC inhibitor pracinostat through a pivotal study. MEI gets $20 million in near-term cash —$15 million up front with a $5 million milestone at the start of the Phase III — along with a $5 million equity investment. And there’s $444 million in milestones on the table for success, along with royalties that can be earned from Helsinn’s marketing efforts”

“Advaxis Inc. ADXS, +5.48% shares spiked 28% in pre-market trade Tuesday after the company announced a $40 million agreement with Amgen Inc. AMGN, -0.15% to develop and commercialize cancer immunotherapy treatment ADXS-NEO. The agreement includes a $40 million upfront payment to Advaxis and a $25 million purchase of the company’s common stock by Amgen, along with sales milestone payments of up to $475 million and additional royalty payments based on global sales.

The 2013 reverse merger was a huge flaw that has created the opportunity we have today. We "only" need $ 8 to $12 million to get all 200 applications of AC5 approved in US and Europe.

With Dr. Norchi's background of being a MIT MBA and former portfolio manager at $ 4 Billion Putnam healthcare fund it would have been so easy to raise $20 million in straight up IPO and been done with it.
Instead they did complicated warrant structure. This benefited us with the opportunity.

Arch has totally changed in last 9 months with a fleet of potential products beyond AC5's 200 applications that no one is focusing on yet.

"The results were good and that takes so much risk out of this going forward."

Agree that the risk portion has been reduced substantially. Arch's
market cap on fully diluted basis $115 millon--The institutions have not bought in yet. At all.

Closure Medical was sold for $ 370 million and AC5 has much much bigger footprint.

Plus all the other patents filed.

Patience Patience.

They own 30% and have a ton of options.

What I would like to see is institutions coming in..... someday soon.